Nazca has acquired a majority stake in Nutris, a leading innovator in functional gummies, signaling a significant investment aimed at fueling the company's ambitious growth and international expansion.

Information on the Target

Nutris is an innovative nutraceutical company specializing in the production of functional gummies, a rapidly growing niche due to its appealing and novel form. The company focuses on creating scientifically validated functional projects aimed at improving health outcomes. With a strong presence in the market, Nutris sells its products through pharmacies, health food stores, and specialty shops.

Founded in 2013 and located in Madrid, Nutris has positioned itself as a leader in the manufacture of functional gummies in Europe, achieving substantial annual growth of 60%. The company has seen its revenue increase from €16 million in 2020 to an estimated €25 million in 2021, with an EBITDA margin around 20%. The founders, Pedro de La Fuente and Inés de Santos, will remain at the helm, ensuring continuity in the company's strategic vision.

Industry Overview in the Target’s Specific Country

The Spanish nutraceutical industry has experienced significant growth, driven by consumer preferences shifting towards natural and functional food products. The growing awareness of health and wellness among consumer

View Source

Similar Deals

InvestIndustrial Grupo Alacant

2024

Growth Equity & Expansion Capital Frozen Food Manufacturing Spain
Talde Private Equity Discarlux

2024

Growth Equity & Expansion Capital Meat Processing Spain
ACON Investments, DeA Capital Alternative Funds Romar Global Care Group

2024

Growth Equity & Expansion Capital Household Products (NEC) Spain
Unigrains Iberia Ñaming

2024

Growth Equity & Expansion Capital Ready-Made Meals Spain
Portobello Capital Eurocebollas

2023

Growth Equity & Expansion Capital Food Ingredients Spain
PHI Industrial Compañía del Trópico

2023

Growth Equity & Expansion Capital Flour Milling Spain

Nazca

invested in

Nutris

in 2021

in a Growth Equity & Expansion Capital deal

Disclosed details

Revenue: $29M

EBITDA: $6M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert